Although autism and FXS are developmental disorders, acute pharmacological inhibition of ADCY1 by NB001 effectively corrects the autism-related symptoms in adult Fmr1 KO mice, suggesting that ADCY1 may be a promising target in treating autism-related symptoms even after the critical developmental window has passed. This evidence concerns the gene FMR1 and fragile X syndrome.